Scheduled versus Pro Re Nata Dosing in the VIEW Trials

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

Medicine, Ophthalmology, Surgery +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Medicine, Ophthalmology, Pharmacotherapy +13

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier, David M. Brown, Victor Chong et al. · Ophthalmology · 2012 · 2.5K citations

Medicine, Ophthalmology, Vision Science +16

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +12

VEGF-Trap: A VEGF blocker with potent antitumor effects

Jocelyn Holash, Sam Davis, Susan D. Croll et al. · Proceedings of the National Academy of Sciences · 2002 · 1.7K citations

Medicine, Oncology, Pharmacology +17